Compare NBIX & CSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | CSL |
|---|---|---|
| Founded | 1992 | 1917 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 14.0B |
| IPO Year | 1996 | 1994 |
| Metric | NBIX | CSL |
|---|---|---|
| Price | $163.88 | $345.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 6 |
| Target Price | $180.91 | ★ $401.67 |
| AVG Volume (30 Days) | ★ 1.1M | 312.0K |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.27% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | 1.91 | ★ 3.10 |
| Revenue | $161,626,000.00 | ★ $5,003,600,000.00 |
| Revenue This Year | $24.73 | $2.59 |
| Revenue Next Year | $13.14 | $4.50 |
| P/E Ratio | ★ $87.58 | $110.35 |
| Revenue Growth | ★ 977.51 | 9.08 |
| 52 Week Low | $122.14 | $293.43 |
| 52 Week High | $169.57 | $435.92 |
| Indicator | NBIX | CSL |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 49.89 |
| Support Level | $134.92 | $339.39 |
| Resistance Level | N/A | $344.68 |
| Average True Range (ATR) | 4.51 | 8.73 |
| MACD | 0.13 | 0.93 |
| Stochastic Oscillator | 67.18 | 80.15 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Carlisle Companies Inc is a holding company that manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. It operates through two segments: Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The majority of revenue comes from Carlisle Construction Materials, and more than half of total revenue is earned in the United States. Carlisle Construction Materials produces premium single-ply roofing products and warranted roof systems, including EPDM, TPO, PVC membrane, and polyiso insulation. Carlisle Weatherproofing Technologies produces building envelope solutions, including waterproofing, moisture protection products, air/vapor barriers, and spray polyurethane foam systems.